Showing results (21-30 of 202) with videos related to
Sort By:
Pageof 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 8, 2008
When to start antiretroviral therapy?Timothy J Wilkin, Roy M GulickCurrent HIV/AIDS Reports|August 11, 2005
Antiretroviral therapy: when and what to start-- an American perspectiveTimothy J Wilkin, Roy M GulickCurrent Infectious Disease Reports|July 18, 2003
Antiretroviral Therapy: When and What to Start-- An American PerspectiveTimothy J. Wilkin, Roy M. GulickHIV Clinical Trials|October 30, 2003
Patient acceptance of self-injected enfuvirtide at 8 and 24 weeksCalvin Cohen, James Hellinger, Margaret Johnson, et al.Antimicrobial Agents and Chemotherapy|December 25, 2002
Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214Martin Stürmer, Schlomo Staszewski, Hans-Wilhelm Doerr, et al.Scandinavian Journal of Infectious Diseases|July 14, 2005
Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosisMarkus Bickel, Christoph Stephan, Carsten Rottmann, et al.Antiviral Therapy|February 5, 2008
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patientsNils von Hentig, Errol Babacan, Schlomo Staszewski, et al.Current HIV Research|May 16, 2009
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?Christoph Stephan, Brenda Dauer, Pavel Khaykin, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income CountriesStanley E Cooper, Joshua Rosenblatt, Roy M GulickPageof 21